Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial

Vladimir Neychev, Seth M Steinberg, Candice Cottle-Delisle, Roxanne Merkel, Naris Nilubol, Jianhua Yao, Paul Meltzer, Karel Pacak, Stephen Marx, Electron Kebebew, Vladimir Neychev, Seth M Steinberg, Candice Cottle-Delisle, Roxanne Merkel, Naris Nilubol, Jianhua Yao, Paul Meltzer, Karel Pacak, Stephen Marx, Electron Kebebew

Abstract

Introduction: Finding the optimal management strategy for patients with advanced, metastatic neuroendocrine tumours (NETs) of the gastrointestinal tract and pancreas is a work in progress. Sunitinib and everolimus are currently approved for the treatment of progressive, unresectable, locally advanced or metastatic low-grade or intermediate-grade pancreatic NETs. However, mutation-targeted therapy with sunitinib or everolimus has not been studied in this patient population.

Methods and analysis: This prospective, open-label phase II clinical trial was designed to determine if mutation-targeting therapy with sunitinib or everolimus for patients with advanced low-grade or intermediate-grade NETs is more effective than historically expected results with progression-free survival (PFS) as the primary end point. Patients ≥18 years of age with progressive, low-grade or intermediate-grade locally advanced or metastatic NETs are eligible for this study. Patients will undergo tumour biopsy (if they are not a surgical candidate) for tumour genotyping. Patients will be assigned to sunitininb or everolimus based on somatic/germline mutations profile. Patients who have disease progression on either sunitinib or everolimus will crossover to the other drug. Treatment will continue until disease progression, unacceptable toxicity, or consent to withdrawal. Using the proposed criteria, 44 patients will be accrued within each treatment group during a 48-month period (a total of 88 patients for the 2 treatments), and followed for up to an additional 12 months (a total of 60 months from entry of the first patient) to achieve 80% power in order to test whether there is an improvement in PFS compared to historically expected results, with a 0.10 α level one-sided significance test.

Ethics and dissemination: The study protocol was approved by the institutional review board of the National Cancer Institute (NCI-IRB Number 15C0040; iRIS Reference Number 339636). The results will be published in a peer-reviewed journal and shared with the worldwide medical community.

Trial registration number: NCT02315625.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Figure 1
Figure 1
Study flow chart. CR, complete response; PR, partial response; SD, stable disease; PD, disease progression.

References

    1. Halfdanarson TR, Rabe KG, Rubin J et al. . Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19:1727–33. 10.1093/annonc/mdn351
    1. Ehehalt F, Saeger HD, Schmidt CM et al. . Neuroendocrine tumors of the pancreas. Oncologist 2009;14:456–67. 10.1634/theoncologist.2008-0259
    1. Oberg K. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes 2009;16:72–8. 10.1097/MED.0b013e328320d845
    1. Panzuto F, Nasoni S, Falconi M et al. . Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083–92. 10.1677/erc.1.01017
    1. Schimmack S, Svejda B, Lawrence B et al. . The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 2011;396:273–98. 10.1007/s00423-011-0739-1
    1. Kulke MH, Anthony LB, Bushnell DL et al. . NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010;39:735–52. 10.1097/MPA.0b013e3181ebb168
    1. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469–92. 10.1053/j.gastro.2008.05.047
    1. Modlin IM, Moss SF, Chung DC et al. . Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 2008;100:1282–9. 10.1093/jnci/djn275
    1. Jensen RT, Berna MJ, Bingham DB et al. . Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008;113(7 Suppl):1807–43. 10.1002/cncr.23648
    1. Khagi S, Saif MW. Neuroendocrine tumors: treatment updates. JOP 2013;14:367–71.
    1. Yao JC, Hassan M, Phan A et al. . One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063–72. 10.1200/JCO.2007.15.4377
    1. Oberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol 2010;21(Suppl 7):vii72–80. 10.1093/annonc/mdq290
    1. Tuveson D, Hanahan D. Translational medicine: cancer lessons from mice to humans. Nature 2011;471:316–17. 10.1038/471316a
    1. Raymond E, Dahan L, Raoul JL et al. . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501–13. 10.1056/NEJMoa1003825
    1. Zitzmann K, De Toni EN, Brand S et al. . The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007;85:54–60. 10.1159/000100057
    1. Yao JC, Shah MH, Ito T et al. . Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364: 514–23. 10.1056/NEJMoa1009290
    1. Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm Des 2012;18:2766–77. 10.2174/138161212800626210
    1. Duerr EM, Mizukami Y, Ng A et al. . Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer 2008;15:243–56. 10.1677/ERC-07-0194
    1. Meric-Bernstam F, Akcakanat A, Chen H et al. . PIK3CA/PTEN mutations and akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 2012;18:1777–89. 10.1158/1078-0432.CCR-11-2123
    1. Missiaglia E, Dalai I, Barbi S et al. . Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010;28:245–55. 10.1200/JCO.2008.21.5988
    1. Dong M, Phan AT, Yao JC. New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clin Cancer Res 2012;18:1830–6. 10.1158/1078-0432.CCR-11-2105
    1. Jiao Y, Shi C, Edil BH et al. . DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331:1199–203. 10.1126/science.1200609
    1. Yao JC, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. Hematol Oncol Clin North Am 2007;21:575, 81; x 10.1016/j.hoc.2007.04.001
    1. Yao JC, Phan AT, Chang DZ et al. . Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311–18. 10.1200/JCO.2008.16.7858
    1. La Rosa S, Uccella S, Finzi G et al. . Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 2003;34:18–27. 10.1053/hupa.2003.56
    1. Kulke MH, Lenz HJ, Meropol NJ et al. . Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403–10. 10.1200/JCO.2007.15.9020
    1. Koch CA, Gimm O, Vortmeyer AO et al. . Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy? Ann N Y Acad Sci 2006;1073:517–26. 10.1196/annals.1353.055
    1. Nilsson O, Wangberg B, Kolby L et al. . Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. Int J Cancer 1995;60:645–51. 10.1002/ijc.2910600514
    1. Tsikitis VL, Wertheim BC, Guerrero MA. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the united states: A seer analysis. J Cancer 2012;3:292–302. 10.7150/jca.4502
    1. Lawrence B, Gustafsson BI, Chan A et al. . The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40:1, 18, vii 10.1016/j.ecl.2010.12.005
    1. Gustafsson BI, Siddique L, Chan A et al. . Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973–2004, and current diagnosis and therapy. Int J Oncol 2008;33:1121–31.
    1. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458–511. 10.1210/er.2003-0014
    1. Ramage JK, Davies AH, Ardill J et al. . Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54(Suppl 4):iv1–16. 10.1136/gut.2004.053314
    1. Falconi M, Plockinger U, Kwekkeboom DJ et al. . Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006;84:196–211. 10.1159/000098012
    1. de Herder WW. Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome). Best Pract Res Clin Gastroenterol 2005;19:705–15. 10.1016/j.bpg.2005.05.007
    1. Saxena A, Chua TC, Chu F et al. . Optimizing the surgical effort in patients with advanced neuroendocrine neoplasm hepatic metastases: a critical analysis of 40 patients treated by hepatic resection and cryoablation. Am J Clin Oncol 2012;35:439–45. 10.1097/COC.0b013e31821bc8dd
    1. Chamberlain RS, Canes D, Brown KT et al. . Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg 2000;190:432–45. 10.1016/S1072-7515(00)00222-2
    1. Plockinger U, Rindi G, Arnold R et al. . Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the european neuroendocrine tumour society (ENETS). Neuroendocrinology 2004;80:394–424. 10.1159/000085237
    1. Akerstrom G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:87–109. 10.1016/j.beem.2006.12.004
    1. Sutcliffe R, Maguire D, Ramage J et al. . Management of neuroendocrine liver metastases. Am J Surg 2004;187:39–46. 10.1016/j.amjsurg.2003.04.007
    1. Kulke MH, Siu LL, Tepper JE et al. . Future directions in the treatment of neuroendocrine tumors: consensus report of the national cancer institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol 2011;29:934–43. 10.1200/JCO.2010.33.2056
    1. Rinke A, Muller HH, Schade-Brittinger C et al. . Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009;27:4656–63. 10.1200/JCO.2009.22.8510

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi